GlassScriptPhysician profile
Lea M Hamila
NPI 1902142078
$7,286.74
in general payments reported to CMS, 2019-2025
33 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,116 · 2022: $1,037 · 2023: $1,866 · 2024: $1,846 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,102 · Education: $30.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,102.22 |
| Education | $30.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,003.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $778.22 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $603.87 | 2021-2024 | |
| Gilead Sciences, INC. | $596.75 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $536.08 | 2021-2024 | |
| Janssen Biotech, INC. | $446.80 | 2021-2023 | Symtuza |
| Exact Sciences Corporation | $372.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $352.68 | 2021-2025 | Xifaxan |
| Ardelyx, INC. | $329.73 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $307.99 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $271.05 | 2022-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.41 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $253.01 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Viiv Healthcare Company | $225.90 | 2021-2025 | Cabenuva, Rukobia, Apretude |
| Lilly USA, LLC | $197.96 | 2021-2024 | Mounjaro, Zepbound |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $103.27 | 2021-2023 | Talicia |
| Janssen Products, LP | $95.96 | 2021 | |
| Seqirus USA INC | $76.07 | 2023-2025 | Fluad Quadrivalent, Flucelvax Quadrivalent, Fluad |
| Abbott Laboratories | $59.12 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $58.45 | 2022 | |
| Phathom Pharmaceuticals, INC. | $55.73 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.32 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $44.62 | 2021 | |
| Merck Sharp & Dohme LLC | $40.77 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Alkermes, INC. | $22.58 | 2025 | Vivitrol |
| Janssen Pharmaceuticals, INC | $20.18 | 2021 | |
| Mannkind Corporation | $19.97 | 2023 | Afrezza |
| Medtronic, INC. | $18.40 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.51 | 2021 | |
| Indivior INC. | $16.39 | 2025 | Sublocade |
| Novartis Pharmaceuticals Corporation | $16.02 | 2025 | |
| Neurocrine Biosciences, INC. | $15.87 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.71 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Hamila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.